Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma

Next Previous
Trial Profile

A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Glioblastoma
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Daiichi Sankyo Company; Plexxikon

Most Recent Events

  • 06 Jan 2020 Status changed from completed to discontinued.
  • 26 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 09 Dec 2014 Planned End Date changed from 1 Sep 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top